AP NEWS
Press release content from Business Wire. The AP news staff was not involved in its creation.
PRESS RELEASE: Paid content from Business Wire
Press release content from Business Wire. The AP news staff was not involved in its creation.

PREDICT-LAA Trial Enrolls First Patient

January 17, 2020 GMT

GENT, Belgium--(BUSINESS WIRE)--Jan 17, 2020--

FEops, a leader in personalized predictive planning for structural heart interventions, is proud to announce that today the first patient has been enrolled in the physician-initiated PREDICT-LAA trial. The trial is led by Righshospitalet (Copenhagen, Denmark) and aims to assess whether the use of FEops HEARTguide™ computer simulations based on cardiac CT-imaging can contribute to better preprocedural planning and improved procedural outcomes of percutaneous LAA closure procedures with the Abbott Amplatzer™ Amulet™ device. The trial is supported by both Abbott and FEops.

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20200117005274/en/

“Today we enrolled the first patient in PREDICT-LAA at our hospital. In a joined effort with 9 other sites, we will test the hypothesis that by using these new computer simulations, a better preprocedural planning of the intervention can be obtained. This is essential information, since today it is not always possible to determine the exact anticipated ‘landing zone’ or ‘position’ of the closure device and, hence, to select the appropriate device size.” said Dr Ole De Backer, Principal Investigator of the PREDICT-LAA

PREDICT-LAA is a prospective, multicenter, randomized controlled trial. In total, 200 patients eligible for percutaneous LAA closure with an Amplatzer ™ Amulet™ device (Abbott, USA) will be enrolled - 100 patients will be allocated to the computational simulation treatment arm and 100 patients to the standard treatment arm. Primary endpoints are closure of the LAA, and presence of device-related thrombus. Estimated enrollment completion date is March 2021.

“Our support together with Abbott in the PREDICT-LAA trial shows our strong commitment to generate a robust body of clinical evidence with FEops HEARTguide, contributing to better procedure planning and patient outcome.” said Christian Vincent, Director Therapy Development at FEops.

FEops HEARTguide TM, currently available on the EU and Canadian market, is a one-in-its-kind cloud based procedure planning environment for structural heart interventions that provides physicians unique insights to evaluate device sizing and positioning pre-operatively using novel computational modeling and simulation technology. Such insights have the power to help improving clinical outcomes in real-world hospital settings. The current release includes workflows for transcatheter aortic valve implantation ( TAVI ) and left atrial appendage occlusion ( LAAo ) procedures.

About FEops

Privately held FEops, headquartered in Gent, Belgium, is a leader in personalized predictive planning for structural heart interventions. In September 2017, FEops announced that it closed a 6 million euros financing, led by Valiance, and joined by existing investors Capricorn Venture Partners and PMV. In December 2019, FEops received a 3.2 million euros grant from the European Innovation Council (EIC) accelerator programme.

FEops contribution to this project was made possible by the funding from the European Union’s Horizon 2020 research and innovation programme under grant agreement No 945698.

www.feops.com

View source version on businesswire.com:https://www.businesswire.com/news/home/20200117005274/en/

CONTACT: Press Contacts

Matthieu De Beule, PhD

CEO

Tel: 00 32 9 292 80 30

Email:matthieu.debeule@feops.com

KEYWORD: BELGIUM EUROPE UNITED STATES NORTH AMERICA MASSACHUSETTS

INDUSTRY KEYWORD: MEDICAL DEVICES HEALTH TECHNOLOGY OTHER HEALTH SOFTWARE BIOTECHNOLOGY

SOURCE: FEops

Copyright Business Wire 2020.

PUB: 01/17/2020 09:00 AM/DISC: 01/17/2020 09:01 AM

http://www.businesswire.com/news/home/20200117005274/en